GlassScriptPhysician profile
Ray B Vaughters
NPI 1568401693
$1,817.19
in general payments reported to CMS, 2019-2025
12 companies · $36.79 in 2025
The $36.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $197 · 2021: $180 · 2022: $39.77 · 2023: $334 · 2024: $61.19 · 2025: $36.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $607.50 | 2019 | |
| Lilly USA, LLC | $425.41 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $189.26 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $121.43 | 2020-2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $119.46 | 2023-2024 | |
| Becton, Dickinson and Company | $105.48 | 2019-2021 | |
| Novo Nordisk INC | $84.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.29 | 2023 | |
| Nevro Corp. | $29.63 | 2021 | |
| Abbott Laboratories | $29.22 | 2019-2025 | |
| Averitas Pharma INC. | $24.13 | 2023 | Qutenza |
| Recordati_rare_diseases_inc. | $21.32 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Vaughters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.